Instructions for Proserin (neostigmine methylsulphate)
Release form Proserin
Tablets
Composition Proserin:
Per 1 tablet: Active substance: Neostigmine methyl sulfate - 0.015 g Auxiliary substances: -sucrose, potato starch, calcium stearate.
English product name
Proserin
Release form
500 μg/1 ml r/v and p/c: amp. 10 pcs
Description:
Solution for in/in and out/to injection 1 ml
neostigmina methylsulfate 500μg
1 ml - ampoules (10) /with knife.amp. or scarif. as required./ - cardboard packs.
ATC codes
N07AA01 Neostigmine
Clinical-pharmacological groups / Group affiliation
Cholinesterase inhibitor
Active substance
neostigmina methylsulfate
Pharmacotherapy group:
Anticholinesterase agent
Testimony Proserin:
To receive inside: gravis myasthenia, motor disorders after brain injury,
paralysis, recovery period after suffering meningitis,
polio,
encephalitis.
For parenteral use:
myasthenia;
motor disturbances after brain injuries; paralysis;
Recovery period after meningitis, polio and encephalitis;
Nevries prevention and treatment of gastrointestinal and bladder atonia;
Weakness of birth (rarely).
As an antidote after anesthesia with non-polarizing muscle relaxants and respiratory depression. In paediatrics is used only for gravis myasthenia.
How to take the drug Proserin:
Used inwards, p/c, v/m and v/v. The dose, method and procedure for the use and duration of therapy are determined individually, depending on the indications, clinical situation, patient age and the dosage form used.
How to take the drug of the tablet Proserin:
In, 30 minutes before meals, adults - 10-15 mg 2-3 times a day, maximum single dose -15 mg, daily - 50 mg. Children: up to 10 years - 1 mg per 1 year of life per day, over 10 years - up to 10 mg/day (no more). The course of treatment (except for myasthenia gravis) - 25-30 days, if necessary - again, in 3-4 weeks. Most of the total daily dose is given during the daytime when the patient is most tired. In case of weakness of labour activity - inside 3 mg 4-6 times a day at intervals of 40 min.
Use in children
It can be used in children according to indications, in doses recommended by age and in dosage forms. The instructions in the instructions for the use of specific forms of neostigmine methylsulfate in children of different ages should be strictly followed.
Nosology (ICD codes)
G09
Effects of inflammatory diseases of the central nervous system
G24
Dystonia (including dyskinesia)
G70
Myasthenia gravis and other neuromuscular synapses disorders
G73.3
Myasthenic syndromes for other diseases classified in other headings
G80
Cerebral palsy
G81
Hemiplegia
G82
Paraplegia and tetraplegia
G83
Other paralytic syndromes
K31.8
Other specified diseases of the stomach and duodenum
K59.8
Other specified functional intestinal disorders
M79.2
Neuralgia and Neuritis Unspecified
N31.2
Neurogenic bladder weakness not classified elsewhere
O62.2
Other weaknesses of labour
T90
Effects of head injuries
Pharmacological effect Proserin:
Cholinesterase is an inhibitor. Synthetic anticholinesterase agent. It reversibly inhibits cholinesterase, which results in the accumulation and enhancement of the action of acetylcholine on organs and tissues and the restoration of neuromuscular conductivity. It causes a reduction in the heart rate, increases the secretion of the glands (salivary, bronchial, sweat and gastrointestinal tract (GI)) and promotes the development of hypersalivation,
bronchoria, increased acidity of gastric juice, constricts the pupil, causes a spasm of accommodation, reduces intraocular pressure, increases the tonus of smooth intestinal musculature (increases peristalsis and relaxes sphincters) and bladder, causes bronchial spasm, tones up skeletal musculature. Proserine is an antagonist of anti-depolarizing curarelike drugs Proserin. However, at high doses proserine may itself cause neuromuscular conduction disruption as a result of acetylcholine accumulation and persistent depolarization in the synapse region. It has a direct N-cholinometic effect.
The action of the drug Proserin coincides with the characteristic effects of the stimulation of cholinergic nerves. In contrast to phyzostigmine, it stimulates the muscles of the intestines, bladder and uterus, has little effect on the heart and does not cause central effects. When administered in therapeutic doses, skeletal muscle H-cholinoreceptors are significantly excited and neuromuscular transmission is enhanced.
